Logo for Spago Nanomedical

Spago Nanomedical Investor Relations Material

Latest events

Logo for Spago Nanomedical

Q1 2024

2 May, 2024
Logo for Spago Nanomedical

Q4 2023

7 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Spago Nanomedical

Access all reports
Spago Nanomedical AB develops nanomedicines for cancer diagnostics and treatment. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project.